Abstract

Our group previously developed a series of bridged nucleic acids (BNAs), including locked nucleic acids (LNAs), amido-bridged nucleic acids (AmNAs), and guanidine-bridged nucleic acids (GuNAs), to impart specific characteristics to oligonucleotides such as high-affinity binding and enhanced enzymatic resistance. In this study, we designed a series of LNA-, AmNA-, and GuNA-modified splice-switching oligonucleotides (SSOs) with different lengths and content modifications. We measured the melting temperature (Tm) of each designed SSO to investigate its binding affinity for RNA strands. We also investigated whether the single-stranded SSOs formed secondary structures using UV melting analysis without complementary RNA. As a result, the AmNA-modified SSOs showed almost the same Tm values as the LNA-modified SSOs, with decreased secondary structure formation in the former. In contrast, the GuNA-modified SSOs showed slightly lower Tm values than the LNA-modified SSOs, with no inhibition of secondary structures. We also evaluated the exon skipping activities of the BNAs in vitro at both the mRNA and protein expression levels. We found that both AmNA-modified SSOs and GuNA-modified SSOs showed higher exon skipping activities than LNA-modified SSOs but each class must be appropriately designed in terms of length and modification content.

Highlights

  • Splicing modulation is becoming a therapeutic strategy for many genetic diseases

  • To investigate the ability of amido-bridged nucleic acids (AmNAs)- and guanidine-bridged nucleic acids (GuNAs)-modified splice-switching oligonucleotides (SSOs) to modulate splicing, we designed a series of SSOs of different lengths (13, 15, and 18-mers) targeting DMD exon 58 and possessing different contents of locked nucleic acids (LNAs), AmNA, and GuNA (Figure 2a and Supplementary Table S1)

  • The in vitro study using stable-expressing cells revealed that both novel chemical modifications (AmNA and GuNA) show higher exon skipping activities than LNA modification when appropriately designed

Read more

Summary

Introduction

The US Food and Drug Administration (FDA) has approved the splice-switching oligonucleotide (SSO) therapeutic drugs eteplirsen, golodirsen, and viltolarsen for the treatment of Duchenne muscular dystrophy and nusinersen for the treatment of spinal muscular atrophy [1]. Only a few chemical modifications have been utilized in the FDA-approved. Eteplirsen, golodirsen, and viltolarsen are phosphorodiamidate morpholino oligomers (PMOs), and nusinersen is a 20 -O-methoxyethyl RNA Recent studies have focused on other properties of SSO chemical modifications, such as the promotion of splicing factor recruitment and inhibition of secondary structure formation [6,14].

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call